Translating dosages from animal models to human clinical trials—revisiting body surface area scaling
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Body surface area (BSA) scaling has been used for prescribing individualized dosages of various drugs and has also been recommended by the U.S. Food and Drug Administration as one method for using data from animal model species to establish safe starting dosages for first‐in‐human clinical trials. Although BSA conversion equations have been used in certain clinical applications for decades, recent recommendations to use BSA to derive interspecies equivalents for therapeutic dosages of drug and natural products are inappropriate. A thorough review of the literature reveals that BSA conversions are based on antiquated science and have little justification in current translational medicine compared to more advanced allometric and physiologically based pharmacokinetic modeling. Misunderstood and misinterpreted use of BSA conversions may have disastrous consequences, including underdosing leading to abandonment of potentially efficacious investigational drugs, and unexpected deadly adverse events. We aim to demonstrate that recent recommendations for BSA are not appropriate for animal‐to‐human dosage conversions and use pharmacokinetic data from resveratrol studies to demonstrate how confusion between the “human equivalent dose” and “pharmacologically active dose” can lead to inappropriate dose recommendations. To optimize drug development, future recommendations for interspecies scaling must be scientifically justified using physiologic, pharmacokinetic, and toxicology data rather than simple BSA conversion.—Blanchard, O. L., Smoliga, J. M. Translating dosages from animal models to human clinical trials—revisiting body surface area scaling. FASEB J. 29, 1629‐1634 (2015). www.fasebj.org
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Concerning dosing, differences in metabolism, weight, distribution volume etc. result in different dosing, and oversimplified approaches for dose prediction are common [87].”
From Animal to human translation: a systematic scoping review of reported concordance rates (2019) · cites this paper as [87]
Citations
Cites
Dose translation from animal to human studies revisited.
Reagan‐Shaw, S., Nihal, M., & Ahmad, N. (2008) · The FASEB Journal · doi:10.1096/fj.07-9574lsf · Cited by 6,524 · cited 10×
“62 mg/kg, or;98 mg for a 60 kg human(3, 55).”
BackgroundMethodInfluentialResveratrol improves health and survival of mice on a high-calorie diet
Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu, V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K., et al. (2006) · Nature · doi:10.1038/nature05354 · Cited by 4,290 · cited 3×
“(51), or any animal model study, into a human equivalent dosage for therapeutic effect.”
BackgroundLagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.013 · Cited by 4,057 · cited 2×
“Reagan-Shaw’s example for the “inappropriate comparisons between studies” for pharmacologic effect in humans stemmed from the discussion of resveratrol dosage in the literatureandpress (3, 51, 52).”
BackgroundKleiber, M. (1932) · Hilgardia · doi:10.3733/hilg.v06n11p315 · Cited by 2,222 · cited 1×
“The statements by Pinkel that blood volume, circulating plasma proteins, and renal function correlated with a surface law had already been disproven in the literature for over a decade when published in 1958, and there is no reason to perpetuate misinformation by allowing it to stay in themodern literature without pro…”
BackgroundCytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
Clinical Methods: The History, Physical, and Laboratory Examinations
Kruse, J. A. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450210108045 · Cited by 2,029
Quantitative Laws in Metabolism and Growth
von Bertalanffy, L. (1957) · The Quarterly Review of Biology · doi:10.1086/401873 · Cited by 2,029 · cited 4×
“The use of allometry for pharmacokinetic prediction originates from work in metabolic scaling, which plotted the formula to fit the metabolic rate and body weight of animals on double logarithmic scale (10, 29, 41).”
BackgroundMethodInfluentialHIGH ABSORPTION BUT VERY LOW BIOAVAILABILITY OF ORAL RESVERATROL IN HUMANS
Walle, T., Hsieh, F., DeLegge, M. H., Oatis, J. E., & Walle, U. K. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000885 · Cited by 1,880
Kleiber, M. (1947) · Physiological Reviews · doi:10.1152/physrev.1947.27.4.511 · Cited by 1,817 · cited 8×
“In 1947, Kleiber (11) made a reductio ad absurdum argument to discredit the claims of Dreyer and Ray (18, 19), which is equally applicable to Pinkel (17) from 1958 and Reagan-Shaw et al. (3) from 2008.”
BackgroundMethodInfluentialLost in translation: animal models and clinical trials in cancer treatment.
(2014) · Europe PMC (PubMed Central) · Cited by 1,033
Boocock, D. J., Faust, G. E. S., Patel, K. R., Schinas, A. M., Brown, V. A., Ducharme, M. P., Booth, T. D., Crowell, J. A., Perloff, M., Gescher, A. J., et al. (2007) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0022 · Cited by 824
Absorption of three wine-related polyphenols in three different matrices by healthy subjects
Goldberg, D. M., Yan, J., & Soleas, G. J. (2003) · Clinical Biochemistry · doi:10.1016/s0009-9120(02)00397-1 · Cited by 683
Metabolism and bioavailability oftrans-resveratrol
Wenzel, E., & Somoza, V. (2005) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200500010 · Cited by 676
Physiologically Based Pharmacokinetic Modeling: Principles and Applications
Gerlowski, L. E., & Jain, R. K. (1983) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600721003 · Cited by 576 · cited 11×
“The observation that clearance of certain small molecules is more rapid in the mouse and rat is dependenton the rateof circulation,where renal andhepatic bloodflow is nearly 4 times higher than in human (29, 30).”
BackgroundMethodInfluentialThe determination and interpretation of the therapeutic index in drug development
Muller, P. Y., & Milton, M. N. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3801 · Cited by 563 · cited 9×
“Despite a wealth of research on pharmacokinetic prediction, suboptimal dosage and unanticipated adverse events can occur when exploring investigational therapeutics in humans (1, 2).”
BackgroundInfluentialHematology: basic principles and practice
Goldman, J. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.77 · Cited by 495
Marier, J.-F., Vachon, P., Gritsas, A., Zhang, J., Moreau, J.-P., & Ducharme, M. P. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033340 · Cited by 480
Allometric scaling of mammalian metabolism
White, C. R., & Seymour, R. S. (2005) · Journal of Experimental Biology · doi:10.1242/jeb.01501 · Cited by 433
Almeida, L., Vaz‐da‐Silva, M., Falcão, A., Soares, E., Costa, R., Loureiro, A. I., Fernandes‐Lopes, C., Rocha, J., Nunes, T., Wright, L., et al. (2009) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200800177 · Cited by 426 · cited 1×
“[2009 (56)], which resulted in a Cmax of 21.”
BackgroundCao, X., Gibbs, S. T., Fang, L., Miller, H. A., Landowski, C. P., Shin, H.-C., Lennernas, H., Zhong, Y., Amidon, G. L., Yu, L. X., et al. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9041-2 · Cited by 388
Inhibition of cancer growth by resveratrol is related to its low bioavailability
Asensi, M., Medina, I., Ortega, A., Carretero, J., Baño, M. C., Obrador, E., & Estrela, J. M. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00911-5 · Cited by 388 · cited 2×
“[2002 (55)] reported that a single dosage of 20 mg/kg in mice yields a Cmax of 592 ng/ml.”
BackgroundCirrito, J. R., Disabato, B. M., Restivo, J. L., Verges, D. K., Goebel, W. D., Sathyan, A., Hayreh, D., D'Angelo, G., Benzinger, T., Yoon, H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107411108 · Cited by 377 · cited 1×
“These examples include protease inhibitors for hepatitis C (32), serotonin reuptake inhibitor for Alzheimer’s disease (33), nuclear transport modifierpeptide to treat inflammation (34), andantibodymediateddelivery of IL-2 for the treatmentof breast cancer (33).”
BackgroundThe use of body surface area as a criterion of drug dosage in cancer chemotherapy.
Pinkel, D. P. (1958) · PubMed · Cited by 344
Resveratrol-Associated Renal Toxicity
Crowell, J. A. (2004) · Toxicological Sciences · doi:10.1093/toxsci/kfh263 · Cited by 319 · cited 1×
“(53), in which 3000 mg/kg can be considered the LD10 in healthy male rats, a safe starting dose can be calculated to be48.”
BackgroundFan, J., & de Lannoy, I. A. M. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.09.007 · Cited by 309
Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991-2001
Baker, S. D., Verweij, J., Rowinsky, E. K., Donehower, R. C., Schellens, J. H. M., Grochow, L. B., & Sparreboom, A. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.24.1883 · Cited by 286 · cited 1×
“(7) acknowledge thatBSA isnot used to establish a therapeutic dosage and state that “although the primary objective of phase I trials is to evaluate drug toxicity, antitumor activity is usually a secondary objective.”
BackgroundMeng, X., Maliakal, P., Lu, H., Lee, M.-J., & Yang, C. S. (2004) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf030582e · Cited by 281
Prediction of the normal blood volume. Relation of blood volume to body habitus.
Feldschuh, J., & Enson, Y. (1977) · Circulation · doi:10.1161/01.cir.56.4.605 · Cited by 262
De Buck, S. S., Sinha, V. K., Fenu, L. A., Nijsen, M. J., Mackie, C. E., & Gilissen, R. A. H. J. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.015644 · Cited by 256 · cited 5×
“From in vivo data on the small molecule of interest, and reported physiologic differences between species, thebasemathematicalmodel canbe adjusted to predict absorption, volume of distribution, exposure, and clearance of a potential therapeutic from early development phases (30, 45, 50).”
BackgroundMethodInfluentialHow to calculate the dose of chemotherapy
Gurney, H. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600139 · Cited by 251 · cited 2×
“According to Gurney (6), BSA adjustments frequently lead to underdosing, and “the inaccuracy of body surface area-dosing is more thanan inconvenience and it is important thatmethods for more accurate dose calculation are determined.””
BackgroundYu, R. Z., Kim, T.-W., Hong, A., Watanabe, T. A., Gaus, H. J., & Geary, R. S. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.012401 · Cited by 244 · cited 1×
“In contrast, the injectable antisense synthetic oligonucleotide, now marketed as Kynamro (Genzyme Corporation, Cambridge, MA, USA) for dyslipidemia, showed desired pharmacokinetics when scaled by milligram per kilogram between model species and man (40).”
BackgroundOf Mice and Humans: Are They the Same?—Implications in Cancer Translational Research: TABLE 1
de Jong, M., & Maina, T. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.065706 · Cited by 228 · cited 2×
“The body structures and function of mammals do not simply scale by BSA or body mass, with many factors affecting the outcome of a drug dosage beyond differences in size (9, 27).”
BackgroundBody Surface Area as a Determinant of Pharmacokinetics and Drug Dosing
Sawyer, M., & Ratain, M. J. (2001) · Investigational New Drugs · doi:10.1023/a:1010639201787 · Cited by 223 · cited 4×
“For instance, Sawyer and Ratain [2001(5)] conclude that BSA scaling “has spread throughout the practice of oncology with little justification,” and “very few of the organ functions that determine pharmacokinetics of a drug are related to body surface area.”
BackgroundInfluentialThe Impact of Aqueous Solubility and Dose on the Pharmacokinetic Profiles of Resveratrol
Das, S., Lin, H.-S., Ho, P. C., & Ng, K.-Y. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9677-1 · Cited by 201
McPhee, F., Sheaffer, A. K., Friborg, J., Hernandez, D., Falk, P., Zhai, G., Levine, S., Chaniewski, S., Yu, F., Barry, D., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01186-12 · Cited by 188 · cited 1×
“These examples include protease inhibitors for hepatitis C (32), serotonin reuptake inhibitor for Alzheimer’s disease (33), nuclear transport modifierpeptide to treat inflammation (34), andantibodymediateddelivery of IL-2 for the treatmentof breast cancer (33).”
Background(1998) · PubMed · Cited by 176
MAHMOOD, I. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.015 · Cited by 170 · cited 8×
“The allometric approach for prediction of pharmacokinetic parameters requires pharmacokinetic data availability for at least 2model species and is prone to high errors but is straightforward for a broad scientific audience, inexpensive, and has been more accurate thanBSA scaling for smallmolecules (14, 29).”
BackgroundMethodInfluentialThe impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials
Marchetti, S., & Schellens, J. H. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603925 · Cited by 167 · cited 1×
“According to Marchetti and Schellens [2007 (37)], “40% of exits from Phase I trials are caused by inappropriate pharmacokinetics of the test compound.”
BackgroundReference values for serum proteins of common laboratory rodent strains.
Zaias, J., Mineau, M., Cray, C., Yoon, D., & Altman, N. H. (2009) · PubMed · Cited by 164
Energy metabolism, body size, and problems of scaling.
Schmidt‐Nielsen, K. (1970) · PubMed · Cited by 152
Schein, P. S., Davis, R. D., Carter, S., Newman, J., Schein, D. R., & Rall, D. P. (1970) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt19701113 · Cited by 146 · cited 2×
“This workhasbeendiscussedbyDixon [1976 (42)] who showed that expressing dosages with BSA or bodymass were similar in their inaccuracies between larger species for calculating toxicity in first-in-human clinical trials (42, 43).”
BackgroundHulbert, A. (2014) · Systems · doi:10.3390/systems2020186 · Cited by 126
Mårlind, J., Kaspar, M., Trachsel, E., Sommavilla, R., Hindle, S., Bacci, C., Giovannoni, L., & Neri, D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5041 · Cited by 123
Johnson, W. D., Morrissey, R. L., Usborne, A. L., Kapetanovic, I., Crowell, J. A., Muzzio, M., & McCormick, D. L. (2011) · Food and Chemical Toxicology · doi:10.1016/j.fct.2011.08.023 · Cited by 119 · cited 1×
“An alternative method to determine a safe starting dose is the FDA’s recommendation of 1/10 of the BSA-scaled lethal dose for 10% of the sample (LD10), also specified by Reagan-Shaw (54).”
MethodChemotherapy Dosing Part I: Scientific Basis for Current Practice and Use of Body Surface Area
Kaestner, S. A., & Sewell, G. (2006) · Clinical Oncology · doi:10.1016/j.clon.2006.10.010 · Cited by 114 · cited 3×
“Correlations of PAD with BSA for specific drugs are simply correlative, havebeenoverstated, and theuseofBSA in clinical practice is not supported by pharmacokinetic data (5, 8, 17, 42).”
BackgroundThe Pharmacokinetic Principles Behind Scaling from Preclinical Results to Phase I Protocols
Mahmood, I., & Balian, J. D. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936010-00001 · Cited by 112 · cited 5×
“Scaling by allometry is not based on physiology and does not consider interspecies differences contributing to the high error rate and multiple pitfalls (14, 41).”
BackgroundMethodInfluentialBlood Collection Techniques in Exotic Small Mammals
Ott‐Joslin, J. E. (2009) · Journal of Exotic Pet Medicine · doi:10.1053/j.jepm.2009.04.002 · Cited by 99
Parrott, N., Jones, H., Paquereau, N., & Lavé, T. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto960308.x · Cited by 93 · cited 2×
“From in vivo data on the small molecule of interest, and reported physiologic differences between species, thebasemathematicalmodel canbe adjusted to predict absorption, volume of distribution, exposure, and clearance of a potential therapeutic from early development phases (30, 45, 50).”
BackgroundAl‐kahtani, M. A., Zuleta, C., Caviedes‐Vidal, E., & Garland, Jr. (2004) · Physiological and Biochemical Zoology · doi:10.1086/420941 · Cited by 90 · cited 1×
“Rodents have a variety of adaptations for different environments independent of BSA or size, specifically relating to urineconcentrating ability for those in arid environments (28).”
BackgroundOf Mice and Men: Divergence of Gene Expression Patterns in Kidney
Cheval, L., Pierrat, F., Rajerison, R., Piquemal, D., & Doucet, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046876 · Cited by 70 · cited 2×
“The body structures and function of mammals do not simply scale by BSA or body mass, with many factors affecting the outcome of a drug dosage beyond differences in size (9, 27).”
BackgroundNovel phenotypes identified by plasma biochemical screening in the mouse
Hough, T., Nolan, P. M., Tsipouri, V., Toye, A. A., Gray, I. C., Goldsworthy, M. E., Moir, L., Cox, R., Clements, S., Glenister, P. H., et al. (2002) · Mammalian Genome · doi:10.1007/s00335-002-2188-1 · Cited by 69
Colom, H., Alfaras, I., Maijó, M., Juan, M. E., & Planas, J. M. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0395-8 · Cited by 44
Dreyer, G., & Ray, W. (1911) · Philosophical Transactions of the Royal Society of London Series B Containing Papers of a Biological Character · doi:10.1098/rstb.1911.0003 · Cited by 38 · cited 3×
“Pinkel supports the claim that blood volume was scalable between species by BSA using works published by Dreyer andRay in 1910 and in 1912 (18, 19), whichwere limited to comparisons amongmice, guineapigs, and rabbits (11, 17).”
BackgroundMethodCompartmental Analysis and its Manifold Applications to Pharmacokinetics
Rescigno, A. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9160-x · Cited by 35 · cited 5×
“Modern physiologically based pharmacokinetic modeling (PBPK), though mathematically complex, is becoming more practical through commercial computer programs (2, 49, 50).”
BackgroundMethodInfluentialProblems in Extrapolating Toxicity Data for Laboratory Animals to Man
Dixon, R. L. (1976) · Environmental Health Perspectives · doi:10.1289/ehp.761343 · Cited by 35 · cited 2×
“This workhasbeendiscussedbyDixon [1976 (42)] who showed that expressing dosages with BSA or bodymass were similar in their inaccuracies between larger species for calculating toxicity in first-in-human clinical trials (42, 43).”
BackgroundDiGiandomenico, A., Veach, R. A., Zienkiewicz, J., Moore, D. J., Wylezinski, L. S., Hutchens, M. A., & Hawiger, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110183 · Cited by 25 · cited 1×
“These examples include protease inhibitors for hepatitis C (32), serotonin reuptake inhibitor for Alzheimer’s disease (33), nuclear transport modifierpeptide to treat inflammation (34), andantibodymediateddelivery of IL-2 for the treatmentof breast cancer (33).”
BackgroundDreyer, G., & Ray, W. (1912) · Philosophical Transactions of the Royal Society of London Series B Containing Papers of a Biological Character · doi:10.1098/rstb.1912.0006 · Cited by 20
Models of Physiology and Physiologically Based Models in Clinical Pharmacology
Atkinson, A. J., & Smith, B. P. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.67 · Cited by 13 · cited 4×
“With the costs and complexity of drug development, the scientific community has a deep interest in exploring andmodeling the differences between model species and humans (45, 48, 49).”
BackgroundInfluentialDreyer, G., & Ray, W. (1912) · Proceedings of the Royal Society of London Series B Containing Papers of a Biological Character · doi:10.1098/rspb.1912.0003 · Cited by 11
Klebovich, I., Kanerva, H., Bojti, E., Urtti, A. O., & Drabant, S. (1998) · Pharmacy and Pharmacology Communications · doi:10.1111/j.2042-7158.1998.tb00520.x · Cited by 11 · cited 1×
“Likewise, the AUC of deramciclane in humans was approximately an order ofmagnitude higher thanwould have been predicted by BSA (1, 39).”
BackgroundProblems in Extrapolating Toxicity Data for Laboratory Animals to Man
Dixon, R. L. (1976) · Environmental Health Perspectives · doi:10.2307/3428236 · Cited by 9
Mahmood, I. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.007187 · Cited by 4 · cited 1×
“The literaturehas examples where allometric conversions do hold true, yet it remains a purely correlative method (2, 47).”
Method
Research works printed but not linked: 4
- Center for Drug Evaluation and Research, 2002, Guidance for Industry and Reviewers: Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers, Draft Guidance
- Rubner M., 1883, Über den einfluss der körpergrösse auf stoff- und kraftwechsel, Zeit. Biol., 19, 536
- Center for Drug Evaluation and Research, 2005, Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers
- Mahmood I., 2005, Interspecies Pharmacokinetic Scaling: Principles and Application of Allometric Scaling
Cited by
Targeting Tumor Necrosis Factor Alpha for Alzheimer’s Disease
Decourt, B., Lahiri, D. K., & Sabbagh, M. N. (2017) · Current Alzheimer Research · doi:10.2174/1567205013666160930110551 · Cited by 371
Animal to human translation: a systematic scoping review of reported concordance rates
Leenaars, C. H. C., Kouwenaar, C., Stafleu, F. R., Bleich, A., Ritskes-Hoitinga, M., De Vries, R. B. M., & Meijboom, F. L. B. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1976-2 · Cited by 314
Sulforaphane Protects against Cardiovascular Disease via Nrf2 Activation
Bai, Y., Wang, X., Zhao, S., Ma, C., Cui, J., & Zheng, Y. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/407580 · Cited by 202
“According to the conversion formula between mice and human [87, 88], the consumption of SFN in human is supposed to be 0.”
Vitamin D, Cognition and Alzheimer’s Disease: The Therapeutic Benefit is in the D-Tails
Landel, V., Annweiler, C., Millet, P., Morello, M., & Féron, F. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150943 · Cited by 185
“Deriving interspecies equivalents for therapeutic interventions has usually been done using Body Surface Area scaling; however, it appears that this might not be as adequate as advanced allometric and physiologically based pharmacokinetic modeling for animal-to-human dosage conversion [141].”
MethodBody surface area formulae: an alarming ambiguity
Redlarski, G., Palkowski, A., & Krawczuk, M. (2016) · Scientific Reports · doi:10.1038/srep27966 · Cited by 159
Metadata
- Authors
- Blanchard, O. L., & Smoliga, J. M.
- Affiliations
- Wilmore Labs Limited Liability Company San Antonio Texas USA
- High Point University (US)
- Corresponding author
- Smoliga, James M.
- ORCID
- Smoliga, James M.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2015-02-05
- Volume
- 29
- Issue
- 5
- Pages
- 1629-1634
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2032445654
- Cited by
- 183
- References
- 61
- Citations by year
- 2026: 23 · 2025: 27 · 2024: 16 · 2023: 14 · 2022: 22 · 2021: 22 · 2020: 14 · 2019: 13 · 2018: 7 · 2017: 8 · 2016: 11 · 2015: 6
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The FASEB Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- interspecies scaling, resveratrol, human equivalent dose, allometric scaling, physiologically based pharmacokinetic modeling, drug dosing, translational medicine, adverse drug reactions
- MeSH terms
- Animals, Body Surface Area, Clinical Trials as Topic, Dose-Response Relationship, Drug, Humans, Species Specificity, Therapeutic Equivalency, Tissue Distribution, Drugs, Investigational, Models, Animal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.